Quiz: Predicting Patient Outcomes in Ovarian Cancer

Article

How much do you know about predicting patient outcomes in ovarian cancer? Take our latest quiz to test your knowledge.

In our July ovarian cancer quiz, you’ll get a chance to test your knowledge on predicting patient outcomes in ovarian cancer. Here’s your first question:

1.  Which of the following are under investigation as potential biomarkers for early detection of ovarian cancer?

A.Circulating tumor DNA

B.Circulating microRNAs

C.Fallopian tube microRNAs

D.All of the above


Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Related Content
The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

Relacorilant/Chemo Show Survival Benefit in Platinum-Resistant Ovarian Cancer

Roman Fabbricatore
April 2nd 2025
Article

The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Future research may explore predictors of interval debulking surgery success and the scope of required surgery in advanced ovarian cancer.

Data Show Need for Specialized Expertise in Advanced Ovarian Cancer Surgery

Russ Conroy
March 19th 2025
Article

Future research may explore predictors of interval debulking surgery success and the scope of required surgery in advanced ovarian cancer.

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Uterine Transposition May Maintain Fertility Following Pelvic Radiotherapy

John Paul Diaz, MD
November 4th 2024
Podcast

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Niraparib/Bevacizumab Maintenance Prolongs Response in Pretreated Ovarian Cancer

Niraparib/Bevacizumab Maintenance Prolongs Response in Pretreated Ovarian Cancer

Ariana Pelosci
March 18th 2025
Article

Results from the NIRVANA-R trial found niraparib/bevacizumab maintenance yielded positive activity in pretreated ovarian cancer.

Socioeconomic or racial disparities may contribute to unchanged overall survival among certain patients with metastatic uterine cancer.

Uterine Cancer Survival Rates Have Improved Despite Higher Mortality Risks

Russ Conroy
March 18th 2025
Article

Socioeconomic or racial disparities may contribute to unchanged overall survival among certain patients with metastatic uterine cancer.